Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-09-15
1996-06-18
Tsang, Cecilia
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546 94, 546112, A61K 3144, C07D45100, C07D22102
Patent
active
055278086
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
The present invention relates to novel fused tricyclic nitrogen containing herterocycles, pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment and prevention of inflammatory and central nervous system disorders, as well as several other disorders. The pharmaceutically active compounds of this invention are substance P receptor antagonists. This invention also relates to novel intermediates used in the synthesis of such substance P receptor antagonists.
Substance P is a naturally occurring undecapeptide belonging to the tachykinin family of peptides, the latter being named because of their prompt stimulatory action on smooth muscle tissue. More specifically, substance P is a pharmacologically active neuropeptide that is produced in mammals (having originally been isolated from gut) and possesses a characteristic amino acid sequence that is illustrated by D. F. Veber et al. in U.S. Pat. No. 4,680,283. The wide involvement of substance P and other tachykinins in the pathophysiology of numerous diseases has been amply demonstrated in the art. For instance, substance P has been shown to be involved in the transmission of pain or migraine (see B. E. B. Sandberg et al., Journal of Medicinal Chemistry, 25, 1009 (1982)), as well as in central nervous system disorders such as anxiety and schizophrenia, in respiratory and inflammatory diseases such as asthma and rheumatoid arthritis, respectively, in rheumatic diseases such as fibrositis, and in gastrointestinal disorders and diseases of the GI tract such as ulcerstive colitis and Crohn's disease, etc. (see D. Regoli in "Trends in Cluster Headache,"edited by F. Sicuteri et al., Elsevier Scientific Publishers, Amsterdam, pp. 85-95 (1987)).
In the recent past, some attempts have been made to provide antagonists for substance P and other tachykinin peptides in order to more effectively treat the various disorders and diseases listed above.
Quinuclidine derivatives and related compounds that exhibit activity as substance P receptor antagonists we referred to in Published PCT International Patent Application No. PCT/US89/05338, filed Nov. 20, 1989, now Published PCT International Patent Application No. WO90/06729 (published May 31, 1990) and now also U.S. Pat. No. 5,162,339.
Piperidine derivatives and related heterocyclic nitrogen-containing compounds that are useful as substance P receptor antagonists are referred to in PCT International Patent Application No. PCT/US90/00116, filed Jan. 4, 1990, which is now Published POT International Patent Application No, W091/09844 (published Jul. 11, 1992).
SUMMARY OF THE INVENTION
The present Invention relates to compounds of the formula ##STR2##
wherein R.sup.1 is cycloalkyl having from five to seven carbon atoms, pyrrolyl, thienyl, pyridyl, phenyl or substituted phenyl, wherein said substituted phenyl is substituted with from one to three substituents Independently selected from fluorine, chlorine, bromine, trifluoromethyl, alkyl having from one to three carbon atoms, alkoxy having from one to three carbon atoms, carboxy, alkoxycarbonyl having from one to three carbon atoms in the alkoxy moiety and benzyloxycarbonyl;
R.sup.2 is furyl, thienyl, pyridyl, indolyl, biphenyl, phenyl or substituted phenyl, wherein said substituted phenyl Is substituted with one or two substituents independently selected from fluorine, chlorine, bromine, trifluoromethyl, alkyl having from one to three carbon atoms, alkoxy having from one to three carbon atoms, carboxy, alkoxycarbonyl having from one to three carbon atoms in the alkoxy moiety and benzyloxycarbonyl; and
R.sup.3 is thienyl, phenyl, fluorophenyl, chlorophenyl or bromophenyl.
The present Invention also relates to the pharmaceutically acceptable acid addition and base salts of compounds of the formula I. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts contai
REFERENCES:
patent: 3506673 (1970-04-01), Warawa et al.
patent: 3534053 (1970-10-01), Sallay et al.
patent: 5162339 (1992-11-01), Lowe, III
Schneider et al, Arch. Pharm. 309, 447 (1976).
DeBenedictis Karen
Ginsburg Paul H.
Pfizer Inc.
Richardson Peter C.
Tsang Cecilia
LandOfFree
Fused tricyclic nitrogen containing heterocycles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused tricyclic nitrogen containing heterocycles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused tricyclic nitrogen containing heterocycles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-223142